Monoclonal antibodies targeting different cell wall antigens of group B streptococcus mediate protection in both Fc-dependent and independent manner

Vaccine

Volumn 29, Issue 24, 2011, Pages 4116-4124

  Senn, Beatrice M ^a   Visram, Zehra ^a   Meinke, Andreas L ^a   Neubauer, Christina ^a   Gelbmann, Dieter ^a   Sinzinger, Jan ^a   Hanner, Markus ^a   Lundberg, Urban ^a   Boisvert, Heike ^b,c   Reinscheid, Dieter ^b,d   von Gabain, Alexander ^a   Nagy, Eszter ^a  

^a INTERCELL AG   (Austria)

^b UNIVERSITY OF ULM   (Germany)

^c FORSYTH INSTITUTE   (United States)

^d BONN RHEIN SIEG UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Anti infective monoclonal antibody; Group B streptococcus; Immune prophylaxis; Protective antigens

Indexed keywords

CELL ANTIGEN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIUM PILUS; CELL WALL; CONTROLLED STUDY; FEMALE; GROUP B STREPTOCOCCAL INFECTION; IMMUNOPROPHYLAXIS; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; CELL WALL; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION, PASSIVE; MICE; PHAGOCYTOSIS; RABBITS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79956155987     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.100     Document Type: Article

References (64)

1. Phares C.R., Lynfield R., Farley M.M., Mohle-Boetani J., Harrison L.H., Petit S., et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008, 299:2056-2065.
2. Heath P.T., Nik Yusoff N.K., Baker C.J. Neonatal meningitis. Arch Dis Child Fetal Neonatal Ed 2003, 88:F173-F178.
3. Schrag S., Gorwitz R., Fultz-Butts K., Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002, 51:1-22.
4. Schrag S.J., Stoll B.J. Early-onset neonatal sepsis in the era of widespread intrapartum chemoprophylaxis. Pediatr Infect Dis J 2006, 25:939-940.
5. Centers of Disease Control and Prevention (CDC) Perinatal group B streptococcal disease after universal screening recommendations - United States, 2003-2005. MMRW 2007, 56:701-705.
6. Centers of Disease Control and Prevention (CDC) Trends in perinatal group B streptococcal disease - United States, 2000-2006. MMRW 2009, 58:109-112.
7. Jordan H.T., Farley M.M., Craig A., Mohle-Boetani J., Harrison L.H., Petit S., et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 2008, 27:1057-1064.
8. Heath P.T., Balfour G., Weisner A.M., Efstratiou A., Lamagni T.L., Tighe H., et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 2004, 363:292-294.
9. Dahesh S., Hensler M.E., Van Sorge N.M., Gertz R.E., Schrag S., Nizet V., et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother 2008, 52:2915-2918.
10. Kimura K., Suzuki S., Wachino J., Kurokawa H., Yamane K., Shibata N., et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 2008, 52:2890-2897.
11. Castor M.L., Whitney C.G., Como-Sabetti K., Facklam R.R., Ferrieri P., Bartkus J.M., et al. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008, 2008:727505.
12. Alarcon A., Pena P., Salas S., Sancha M., Omenaca F. Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis. Pediatr Infect Dis J 2004, 23:295-299.
13. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehrenkranz R.A., et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002, 347:240-247.
14. Glasgow T.S., Speakman M., Firth S., James B., Byington C.L., Young P.C. Clinical and economic outcomes for term infants associated with increasing administration of antibiotics to their mothers. Paediatr Perinat Epidemiol 2007, 21:338-346.
15. Edwards M.S. Group B streptococcal conjugate vaccine: a timely concept for which the time has come. Hum Vaccin 2008, 4:444-448.
16. Johri A.K., Paoletti L.C., Glaser P., Dua M., Sharma P.K., Grandi G., et al. Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol 2006, 4:932-942.
17. Maisey H.C., Doran K.S., Nizet V. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Rev Mol Med 2008, 10:e27.
18. Schubert A., Zakikhany K., Schreiner M., Frank R., Spellerberg B., Eikmanns B.J., et al. A fibrinogen receptor from group B Streptococcus interacts with fibrinogen by repetitive units with novel ligand binding sites. Mol Microbiol 2002, 46:557-569.
19. Schubert A., Zakikhany K., Pietrocola G., Meinke A., Speziale P., Eikmanns B.J., et al. The fibrinogen receptor FbsA promotes adherence of Streptococcus agalactiae to human epithelial cells. Infect Immun 2004, 72:6197-6205.
20. Lindahl G., Stalhammar-Carlemalm M., Areschoug T. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev 2005, 18:102-127.
21. Santi I., Scarselli M., Mariani M., Pezzicoli A., Masignani V., Taddei A., et al. BibA: a novel immunogenic bacterial adhesin contributing to group B Streptococcus survival in human blood. Mol Microbiol 2007, 63:754-767.
22. Santi I., Maione D., Galeotti C.L., Grandi G., Telford J.L., Soriani M. BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. J Infect Dis 2009, 200:564-570.
23. Dramsi S., Caliot E., Bonne I., Guadagnini S., Prevost M.C., Kojadinovical M., et al. Assembly and role of pili in group B streptococci. Mol Microbiol 2006, 60:1401-1413.
24. Lauer P., Rinaudo C.D., Soriani M., Margarit I., Maione D., Rosini R., et al. Genome analysis reveals pili in Group B Streptococcus. Science 2005, 309:105.
25. Rosini R., Rinaudo C.D., Soriani M., Lauer P., Mora M., Maione D., et al. Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol 2006, 61:126-141.
26. Schroeder H.W., Mortari F., Shiokawa S., Kirkham P.M., Elgavish R.A., Bertrand F.E. Developmental regulation of the human antibody repertoire. Ann NY Acad Sci 1995, 764:242-260.
27. Simister N.E. Placental transport of immunoglobulin G. Vaccine 2003, 21:3365-3369.
28. Splawski J.B., Jelinek D.F., Lipsky P.E. Delineation of the functional capacity of human neonatal lymphocytes. J Clin Invest 1991, 87:545-553.
29. Harkensee C., Brodlie M., Embleton N.D., McKean M. Passive immunisation of preterm infants with palivizumab against RSV infection. J Infect 2006, 52:2-8.
30. Meinke A, Nagy E, Hanner M, Horky M, Kallenda S, Prustomersky S. S. agalactiae antigens. Patent WO/2004/099242; 2004. Available at: [accessed 25 August 2010]. http://www.wipo.int/pctdb/en/.
31. Meinke A.L., Senn B.M., Visram Z., Henics T.Z., Minh D.B., Schüler W., et al. Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens. Vaccine 2010, 28:6997-7008.
32. Etz H., Minh D.B., Henics T., Dryla A., Winkler B., Triska C., et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 2002, 99:6573-6578.
33. Kuklin N.A., Clark D.J., Secore S., Cook J., Cope L.D., McNeely T., et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006, 74:2215-2223.
34. Giefing C., Meinke A., Hanner M., Henics T., Bui Minh D., Gelbmann D., et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of Pneumococcus with human antibodies. J Exp Med 2008, 205:117-131.
35. Glaser P, Rusniok C., Buchrieser C., Chevalier F., Frangeul L., Msadek T., et al. Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol Microbiol 2002, 45:1499-1513.
36. Senn B, Nagy E, Meinke A, von Gabain A, Maierhofer B, Stierschneider U, et al. Protective antigens of S. agalactiae and combinations thereof. Patent WO/2008/084072; 2008. Available at: [accessed 25 August 2010]. http://www.wipo.int/pctdb/en/.
37. Reinscheid D, Gutekunst H, Schubert A, Eikmanns BJ, Meinke A. Nucleic acids coding for adhesion factor of Group B Streptococcus, adhesion factors of Group B Streptococcus and further use thereof. Patent WO/2004/035618; 2004. Available at: [accessed 25 August 2010]. http://www.wipo.int/pctdb/en/.
38. Maione D., Margarit I., Rinaudo C.D., Masignani V., Mora M., Scarselli M., et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005, 309:148-150.
39. Samen U., Gottschalk B., Eikmanns B.J., Reinscheid D.J. Relevance of peptide uptake systems to the physiology and virulence of Streptococcus agalactiae. J Bacteriol 2004, 186:1398-1408.
40. Brodeur B.R., Boyer M., Charlebois I., Hamel J., Couture F., Rioux C.R., et al. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect Immun 2000, 68:5610-5618.
41. Martin D., Rioux S., Gagnon E., Boyer M., Hamel J., Charland N., et al. Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein. Infect Immun 2002, 70:4897-4901.
42. Tenenbaum T., Bloier C., Adam R., Reinscheid D.J., Schroten H. Adherence to and invasion of human brain microvascular endothelial cells are promoted by fibrinogen-binding protein FbsA of Streptococcus agalactiae. Infect Immun 2005, 73:4404-4409.
43. Konto-Ghiorghi Y., Mairey E., Mallet A., Dumenil G., Caliot E., Trieu-Cuot P., et al. Dual role for pilus in adherence to epithelial cells and biofilm formation in Streptococcus agalactiae. PLoS Pathog 2009, 5:e1000422.
44. Margarit I., Rinaudo C.D., Galeotti C.L., Maione D., Ghezzo C., Buttazzoni E., et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009, 199:108-115.
45. Rinaudo C.D., Rosini R., Galeotti C.L., Berti F., Necchi F., Reguzzi V., et al. Specific involvement of pilus type 2a in biofilm formation in group B Streptococcus. PLoS One 2010, 5:e9216.
46. Brochet M., Couvé E., Zouine M., Vallaeys T., Rusniok C., Lamy M.C., et al. Genomic diversity and evolution within the species Streptococcus agalactiae. Microbes Infect 2006, 8:1227-1243.
47. Lamy M.C., Dramsi S., Billoët A., Réglier-Poupet H., Tazi A., Raymond J., et al. Rapid detection of the " highly virulent" group B Streptococcus ST-17 clone. Microbes Infect 2006, 8:1714-1722.
48. Manning S.D., Springman A.C., Lehotzky E., Lewis M.A., Whittam T.S., Davies H.D. Multilocus sequence types associated with neonatal group B streptococcal sepsis and meningitis in Canada. J Clin Microbiol 2009, 47:1143-1148.
49. Poyart C., Réglier-Poupet H., Tazi A., Billoët A., Dmytruk N., Bidet P., et al. Invasive group B streptococcal infections in infants, France. Emerg Infect Dis 2008, 14:1647-1649.
50. Egan M.L., Pritchard D.G., Dillon H.C., Gray B.M. Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies. J Exp Med 1983, 158:1006-1011.
51. Shigeoka A.O., Pincus S.H., Rote N.S., Hill H.R. Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus. J Infect Dis 1984, 149:363-372.
52. Teti G., Calapai M., Calogero G., Tomasello F., Mancuso G., Galli A., et al. Protective activity of murine monoclonal antibodies directed against the capsular polysaccharide of type III group B streptococci. Hybridoma 1992, 11:13-22.
53. Ricci M.L., von Hunolstein C., Gomez M.J., Parisi L., Tissi L., Orefici G. Protective activity of a murine monoclonal antibody against acute and chronic experimental infection with type IV group B streptococcus. J Med Microbiol 1996, 44:475-481.
54. Raff H.V., Siscoe P.J., Wolff E.A., Maloney G., Shuford W. Human monoclonal antibodies to group B streptococcus. Reactivity and in vivo protection against multiple serotypes. J Exp Med 1988, 168:905-917.
55. Hill H.R., Kelsey D.K., Gonzales L.A., Raff H.V. Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease. Clin Immunol Immunopathol 1992, 62:S87-S91.
56. Marques M.B., Kasper D.L., Shroff A., Michon F., Jennings H.J., Wessels M.R. Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine. Infect Immun 1994, 62:1593-1599.
57. Madoff L.C., Michel J.L., Kasper D.L. A monoclonal antibody identifies a protective C-protein alpha-antigen epitope in group B streptococci. Infect Immun 1991, 59:204-210.
58. Cheng Q., Carlson B., Pillai S., Eby R., Edwards L., Olmsted S.B., et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect Immun 2001, 69:2302-2308.
59. Ohlsson A., Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2010, (3). CD001239.
60. Cohen-Wolkowiez M., Benjamin D.K., Capparelli E. Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. Curr Opin Pediatr 2009, 21:177-181.
61. Weisman L.E., Anthony B.F., Hemming V.G., Fischer G.W. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates. J Pediatr 1993, 122:929-937.
62. Hill H.R., Gonzales L.A., Knappe W.A., Fischer G.W., Kelsey D.K., Raff H.V. Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci. J Infect Dis 1991, 163:792-798.
63. Weisman L.E. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature. Arch Pediatr 2007, 14(Suppl. 1):S31-S34.
64. Weisman L.E., Thackray H.M., Garcia-Prats J.A., Nesin M., Schneider J.H., Fretz J., et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother 2009, 53:2879-2886.